Cited by 1,192Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchProtein Kinase Regulation and GTPase Signaling

The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Open access

Yun, Cai-Hong, Boggon, Titus J., Li, Yiqun, Woo, Michele S., Greulich, Heidi, Meyerson, Matthew, Eck, Michael J.·2007·Cancer Cell

DOI 10.1016/j.ccr.2006.12.017PMC PMC1939942

Open this paper in CoChat — free account Open PDF

Abstract

Mutations in the EGFR kinase are a cause of non-small-cell lung cancer. To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and determined their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine. We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro. Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant. Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2006.12.017

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse‐Kunstleve, R. W., Jiang, J., Kuszewski, J. J., Nilges, M., Pannu, N., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,723
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796
Improved methods for building protein models in electron density maps and the location of errors in these models
Jones, T. A., Zou, J.-Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,616
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
Schüttelkopf, A. W., & van Aalten, D. M. F. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904011679 · Cited by 4,837
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

Flagged first, then by citations

Show all 54 references

2 of the 54 references couldn’t be matched to a known paper.

Sorted by citations

Items 501–600 of 1,000

BRAF oncogenic mutants evade autoinhibition through a common mechanism
Lavoie, H., Jin, T., Lajoie, D., Décossas, M., Gendron, P., Wang, B., Filandr, F., Sahmi, M., Jo, C. H., Weber, S., et al. (2025) · Science · doi:10.1126/science.adp2742 · Cited by 26
Pockets as structural descriptors of EGFR kinase conformations
Hasenahuer, M. A., Barletta, G. P., Fernández-Alberti, S., Parisi, G. D., & Fornasari, M. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189147 · Cited by 23
Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell lines
Zhao, L., Fan, T., Shi, Z., Ding, C., Zhang, C., Yuan, Z., Sun, Q., Tan, C., Chu, B., & Jiang, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113173 · Cited by 24
Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation
Zhang, B., Xu, Z., Liu, Q., Xia, S., Liu, Z., Liao, Z., & Gou, S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105420 · Cited by 24
Novel bis pyrimidine-pyrazolone and pyridinyl-4,5-dihydropyrimido[2,1[1]-c,1,2,4]triazepine utilized ultrasonic energy, anti-proliferative activity, docking simulation, and theoretical investigation
Aboelnaga, A., Soror, S., Nassar, E., El‐Abbady, S. A., & Fahim, A. M. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136517 · Cited by 24
Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivatives
Parsai, S., Keck, R. W., Skrzypczak‐Jankun, E., & Jankun, J. (2013) · Oncology Letters · doi:10.3892/ol.2013.1679 · Cited by 24
“Cyclohexanone analogs fit in the active site of EGFR, as shown by molecular docking (59).”
Influential
Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer
Zhang, L., Fan, C., Guo, Z., Li, Y., Zhao, S., Yang, S., Yang, Y., Zhu, J., & Lin, D. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.032 · Cited by 24
Self-citation
Purposely engineered drug–target mismatches for entropy-based drug optimization
Fernández, A., Fraser, C. M., & Scott, R. (2011) · Trends in biotechnology · doi:10.1016/j.tibtech.2011.07.003 · Cited by 25
In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition
Patel, H., Pawara, R. H., & Surana, S. J. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.03.026 · Cited by 24
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Steen, N. V. D., Giovannetti, E., Carbone, D., Leonetti, A., Rolfo, C. D., & Peters, G. J. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.13 · Cited by 23
Chemoenzymatic Synthesis of 3′-Deoxy-3′,4′-didehydro-cytidine triphosphate (ddhCTP)
Lee, J. H., Wood, J. M., Almo, S. C., Evans, G. B., Harris, L. D., & Grove, T. L. (2023) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.3c00014 · Cited by 23
Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non‐small‐cell lung cancer: Systematic review and meta analysis
Liu, Y., Ren, Z., Wang, J., & Zhang, S. (2016) · Thoracic Cancer · doi:10.1111/1759-7714.12343 · Cited by 23
Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants
García-Godoy, M. J., López-Camacho, E., García-Nieto, J., Nebro, A. J., & Aldana-Montes, J. F. (2016) · Molecules · doi:10.3390/molecules21111575 · Cited by 23
Effect of double mutations T790M/L858R on conformation and drug-resistant mechanism of epidermal growth factor receptor explored by molecular dynamics simulations
Yan, F., Liu, X., Zhang, S., Su, J., Zhang, Q., & Chen, J. (2018) · RSC Advances · doi:10.1039/c8ra06844e · Cited by 23
The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus
Lu, K., Wu, M.-Y., Wang, C., Wang, C., Chung, W., Chung, W., & Chen, C. (2019) · Cells · doi:10.3390/cells8101213 · Cited by 23
Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
Bartelink, I. H., van de Stadt, E. A., Leeuwerik, A. F., Thijssen, V. L., Hupsel, J., Nieuwendijk, J. D., Bahce, I., Yaqub, M. M., & Hendrikse, N. H. (2022) · Pharmaceuticals · doi:10.3390/ph15070796 · Cited by 22
Emerging treatment for advanced lung cancer withEGFRmutation
Inal, C., Yilmaz, E., Piperdi, B., Perez-Soler, R., & Cheng, H. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1058778 · Cited by 23
“Another mutation in exon 20 involving substitution of methionine for threonine at position 790 (T790M, so-called ‘gatekeeper mutation’) confers resistance to TKIs due to steric hindrance blocking erlotinib to bind and increased affinity of ATP.”
BackgroundInfluential
Finding chemical drugs for genetic diseases
Sun, H., Hou, T., & Zhang, H. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.013 · Cited by 23
A Water-Based Mechanism of Specificity and Resistance for Lapatinib with ErbB Family Kinases
Huang, Y., & Rizzo, R. C. (2012) · Biochemistry · doi:10.1021/bi2016553 · Cited by 23
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
Reguart, N. (2010) · Cancer Management and Research · doi:10.2147/cmar.s5398 · Cited by 23
Discovery of novel small molecule EGFR inhibitory leads by structure and ligand-based virtual screening
Mahajan, P., Suri, N., Mehra, R., Gupta, M., Kumar, A., Singh, S. K., & Nargotra, A. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-016-1728-2 · Cited by 23
Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase
Ruan, Z., Katiyar, S., & Kannan, N. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00572 · Cited by 23
Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors
Valley, C. C., Lewis, A. K., & Sachs, J. N. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.01.016 · Cited by 23
“Furthermore, crystal structures of the kinase dimer demonstrate how EGFR mutations, such as those associated with non-small cell lung carcinoma [28–30], lead to conformational changes in kinases that are similar to those associated with activation [27,31,32].”
Background
Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFRL858R/T790M NSCLCs by the conformation constrained strategy
Chen, Y., Yang, L., Qiao, H., Cheng, Z., Xie, J., Zhou, W., Huang, X., Jiang, Y., Yu, B., & Zhao, W. H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112388 · Cited by 24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia
Cheng, W., Yuan, Y., Qiu, N., Peng, P., Sheng, R., & Hu, Y. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.10.038 · Cited by 23
Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy
Wang, Y., Yang, P.-C., Zhang, J., & Sun, J. (2024) · Molecules · doi:10.3390/molecules29071448 · Cited by 22
“Structurally, EGFR consists of an extracellular ligand-binding domain, a single transmembrane domain, an intracellular tyrosine kinase domain, and a C-terminal tail [1].”
Background
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance
Whitehead, C. E., Ziemke, E. K., Frankowski-McGregor, C. L., Mumby, R. A., Chung, J., Li, J., Osher, N., Coker, O., Baladandayuthapani, V., Kopetz, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00781-6 · Cited by 27
“22) and omipalisib 23 bound to EGFR and PI3Kγ, respectively (Fig.”
Metal‐Containing Pharmacophores in Molecularly Targeted Anticancer Therapies and Diagnostics
Yang, M., & Bierbach, U. (2016) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201601149 · Cited by 22
CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor
Liu, B., Song, S., Setroikromo, R., Chen, S., Hu, W., Chen, D., van der Wekken, A. J., Melgert, B. N., Timens, W., van den Berg, A., et al. (2019) · Cancers · doi:10.3390/cancers11040455 · Cited by 22
“It is not surprising that previous studies have shown that gefitinib is not efficient for the treatment of NSCLC patients with wild-type EGFR, because gefitinib has a higher affinity to the mutated version of EGFR, such as L858R point mutation, as compared to wild-type EGFR [34].”
Flavonoids as receptor tyrosine kinase inhibitors in lung cancer
Dev, S. S., Farghadani, R., Abidin, S. A. Z., Othman, I., & Naidu, R. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105845 · Cited by 22
“The well-known EGFR-TKI, gefitinib, also forms a single hydrogen bond to this hinge (Yun et al., 2007).”
Design, synthesis, molecular modeling and anti-breast cancer activity of novel quinazolin-4-one derivatives linked to thiazolidinone, oxadiazole or pyrazole moieties
Ahmed, M. F. E., Belal, A., & Youns, M. (2015) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1357-1 · Cited by 22
“Overexpression of the EGFR is noticed in numerous human malignancies; hence, targeting the ATP binding site of the EGFR by small molecules that act as tyrosine kinase inhibitors is considered a strategy for cancer treatment (Yun et al., 2007).”
Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors
Kim, Y., Apetri, M. M., Luo, B.-B., Settleman, J., & Anderson, K. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0326 · Cited by 25
“The current study was designed to address the following mechanistic questions related to the clinical efficacy of gefitinib and erlotinib: (1) Are differences in drug responsiveness observed in EGFR autophosphorylation patterns for individual tyrosines in 32D cells expressing WT and L858R forms of EGFR? ; (2) Are some…”
Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer
He, C., Zheng, L., Xu, Y., Liu, M., Li, Y., & Xu, J. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.07.012 · Cited by 22
Self-citation
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents
Zuo, S., Zhang, S. M., Mao, S., Xie, X., Xiao, X., Xin, M.-H., Xuan, W., He, Y., Cao, Y., & Zhang, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.12.001 · Cited by 22
The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor
Mohyeldin, M. M., Akl, M. R., Ebrahim, H. Y., Dragoi, A. M., Dykes, S. S., Cardelli, J. A., & Sayed, K. A. E. (2016) · Oncotarget · doi:10.18632/oncotarget.8681 · Cited by 22
“Early identification of new hit abilities to inhibit wild-type and mutant kinases is essential for subsequent drug development process to design drugs useful for patients harboring c-Met mutations [20].”
Effect of Clustering Algorithm on Establishing Markov State Model for Molecular Dynamics Simulations
Li, Y., & Dong, Z. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00181 · Cited by 22
Self-citation
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
Hsu, Y. C., Coumar, M. S., Wang, W.-C., Shiao, H., Ke, Y., Lin, W., Kuo, C., Chang, C.-W., Kuo, F., Chen, P.-Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13369 · Cited by 22
“Similarly, gefinib, an approved treatment for non-small cell lung cancer target EGFR which is mutated and the cause for aberrant signaling in a set of lung cancer patients [32].”
Background
The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR
Mohyeldin, M. M., Akl, M. R., Siddique, A. B., Hassan, H. M., & Sayed, K. A. E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.003 · Cited by 21
“Both Met793 and Pro794 lie in the hinge of the kinase, which connects the N and C lobes [32].”
Leak Proof PDBBind: A Reorganized Dataset of Protein-Ligand Complexes for More Generalizable Binding Affinity PredictionPreprint
Li, J., Guan, X., Zhang, O., Sun, K., Wang, Y., Bagni, D., & Head-Gordon, T. L. (2023) · PubMed · doi:10.48550/arxiv.2308.09639 · Cited by 22
Imidazole-Derived Alkyl and Aryl Ethers: Synthesis, Characterization, In Vitro Anticancer and Antioxidant Activities, Carbonic Anhydrase I–II Inhibition Properties, and In Silico Studies
Faris, M., Bostancı, H. E., Özcan, İ., Öztürk, M., Koçyiğit, Ü. M., Erdoğan, T., & Tahtacı, H. (2024) · ACS Omega · doi:10.1021/acsomega.4c00028 · Cited by 21
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update
Roskoski, R. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107805 · Cited by 21
Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers
Malik, V., Kumar, V., Kaul, S. C., Wadhwa, R., & Sundar, D. (2021) · Biomolecules · doi:10.3390/biom11020160 · Cited by 22
“The initial crystal structure of Chain A of wildtype active conformation of EGFR complexed with ATP was retrieved from Protein Data Bank (PDB) with PDB ID: 2ITX [48].”
Method
Biomarkers and transcriptome profiling of lung cancer
Chen, H., Yu, S., Li, K.-C., & Yang, P. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02154.x · Cited by 21
Patients harboring epidermal growth factor receptor ( EGFR) double mutations had a lower objective response rate than those with a single mutation in non‐small cell lung cancer when treated with EGFR ‐tyrosine kinase inhibitors
Wei, Z., An, T., Wang, Z., Chen, K., Bai, H., Zhu, G., Duan, J., Wu, M., Yang, L., Zhuo, M., et al. (2013) · Thoracic Cancer · doi:10.1111/1759-7714.12068 · Cited by 21
Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
Augustin, A., Lamerz, J., Meistermann, H., Golling, S., Scheiblich, S., Hermann, J. C., Duchâteau-Nguyen, G., Tzouros, M., Avila, D. W., Langen, H., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0880 · Cited by 21
“resolved crystal structures of EGFR and ILK (24, 25), we examined whether the binding of erlotinib to ILK was different from gefitinib, which might explain the discrepancies in their binding profiles toward the IPP complex.”
Background
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients
Wang, Y., Li, R. Q., AI, Y. Q., Zhang, J., Zhao, P., Li, Y., He, W., Xia, Y., & Li, W. H. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1300-4 · Cited by 21
“Mutant forms of exon 19 deletion and L858R mutation had a reduced affinity for its natural substrate ATP, but equivalent or increased affinity for reversible EGFR-TKIs, which explained why tumors with these EGFR mutations had higher sensitivity to TKIs [24].”
BackgroundSelf-citation
Oncogenic growth factor signaling mediating tumor escape from cellular immunity
Concha-Benavente, F., & Ferris, R. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.004 · Cited by 20
PARP inhibitors as precision medicine for cancer treatment
Du, Y., Yamaguchi, H., Hsu, J. L., & Hung, M. (2017) · National Science Review · doi:10.1093/nsr/nwx027 · Cited by 20
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
Zhang, W., Wei, Y., Yu, D., Xu, J., & Peng, J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4685-y · Cited by 21
Evaluation of Raman spectroscopy for diagnosing EGFR mutation status in lung adenocarcinoma
Wang, L., Zhang, Z., Huang, L., Li, W., Lü, Q., Wen, M., Guo, T., Fan, J., Wang, X., Zhang, X., et al. (2013) · The Analyst · doi:10.1039/c3an01381b · Cited by 21
Optimization of gefitinib analogues with potent anticancer activity
Yin, K.-H., Hsieh, Y.-H., Sulake, R. S., Wang, S., Chao, J., & Chen, C. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.09.056 · Cited by 21
Molecular docking analysis of podophyllotoxin derivatives in Sulawesi propolis as potent inhibitors of protein kinases
Flamandita, D., Lischer, K., Pratamı, D. K., Aditama, R., & Sahlan, M. (2020) · AIP conference proceedings · doi:10.1063/5.0002596 · Cited by 21
Parametric Models for Understanding Atomic Trajectories in Different Domains of Lung Cancer Causing Protein
Qureshi, R., Nawaz, M., Ghosh, A., & Yan, H. (2019) · IEEE Access · doi:10.1109/access.2019.2918294 · Cited by 20
Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies
Opo, F. A. D. M., Moulay, M., Zari, A., Alqaderi, A., Alkarim, S., Zari, T. A., Bhuiyan, M. A., Mahmoud, M. M., Aljoud, F., Suhail, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1027890 · Cited by 20
“The nucleotide binding positions vary from 718 to 726 and 790 to 791 (Yun et al., 2007; Jura et al., 2009).”
Background
Antitumor activity and mechanisms of dual EGFR/DNA-targeting strategy for the treatment of lung cancer with EGFRL858R/T790M mutation
Dai, L., Qin, F., Xie, Y., Zhang, B., Zhang, Z., Liang, S., Chen, F., Huang, X., & Wang, H. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106510 · Cited by 20
Design, synthesis, in silico, and pharmacological evaluation of novel quinoline derivatives containing substituted piperazine moieties as potential anti-breast cancer agents
Priya, M. G. R., Solomon, V. R., Nagarajan, H., Jeyakanthan, J., Kumar, D., & Mahesh, J. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101359 · Cited by 20
Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents
Li, S., Guo, C., Sun, X., Li, Y., Zhao, H., Zhan, D., Lan, M., & Tang, Y. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.021 · Cited by 20
Self-citation
The aqueous extract of Brucea javanica suppresses cell growth and alleviates tumorigenesis of human lung cancer cells by targeting mutated epidermal growth factor receptor
Kim, S.-H., Liu, C., Fan, P.-W., Hsieh, C.-H., Lin, H.-Y., Lee, M.-C., & Fang, K. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s117443 · Cited by 20
“However, patients receiving tailored target therapy gradually develop secondary mutations in EGFR, which results in relapse.(11) The acquired somatic mutations at amino acid at 790 of EGFR (T790M) block steric binding of gefitinib and trigger resistance.”
Background
RETRACTED: Using Data Mining Methods for Predicting Sequential Maintenance Activities
Rezig, S., Achour, Z., & Rezg, N. (2018) · Applied Sciences · doi:10.3390/app8112184 · Cited by 20
“Other researchers have investigated the weighted itemset mining considering the occurrence of the item along with its weight or importance [10].”
Background
Retracted
Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer
Sanomachi, T., Suzuki, S., Togashi, K., Seino, S., Yoshioka, T., Kitanaka, C., Okada, M., & Yamamoto, M. (2019) · Anticancer Research · doi:10.21873/anticanres.13667 · Cited by 19
Taking Quinazoline as a General Support‐Nog to Design Potent and Selective Kinase Inhibitors: Application to FMS‐like Tyrosine Kinase 3
Li, W., Chen, J., Zheng, R., Zhang, W., Cao, Z., Yang, L., Qing, X., Zhou, L., Yang, L., Yu, L., et al. (2010) · ChemMedChem · doi:10.1002/cmdc.200900537 · Cited by 20
Substrate-Induced Facilitated Dissociation of the Competitive Inhibitor from the Active Site of O-Acetyl Serine Sulfhydrylase Reveals a Competitive-Allostery Mechanism
Singh, A. K., Ekka, M. K., Kaushik, A., Pandya, V. K., Singh, R. P., Banerjee, S., Mittal, M., Singh, V., & Kumaran, S. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00500 · Cited by 20
Predicting Pathways between Distant Configurations for Biomolecules
Röder, K., & Wales, D. J. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00370 · Cited by 19
Distinct roles of UVRAG and EGFR signaling in skeletal muscle homeostasis
Kim, M. J., Febbraro, D., Farkona, S., Gillmore, T., Son, J. E., Regeenes, R., Chang, H. H., Pollock‐Tahiri, E., Yang, J., Park, Y. J., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101185 · Cited by 19
“This mutation enhances the downstream EGFR signaling pathways due to a conformational change in the receptor [29,30].”
BackgroundSelf-citation
Mechanistic insight toward EGFR activation induced by ATP: role of mutations and water in ATP binding patterns
Laudadio, E., Mobbili, G., Sorci, L., Galeazzi, R., & Minnelli, C. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2108497 · Cited by 18
Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR WT , EGFR T790M , and EGFR L858R )
Al-Hamd, M. G. A., Tawfik, H. O., Abdullah, O., Yamaguchi, K., Sugiura, M., Mehany, A. B. M., El‐Hamamsy, M. H., & El-Moselhy, T. F. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2241674 · Cited by 19
“It ’ s the most common EGFR mutation, accounting for 35% of all mutations 66 .”
Background
Electrochemical-Fluorescent Bimodal Biosensor Based on Dual CRISPR-Cas12a Multiple Cascade Amplification for ctDNA Detection
Zhang, H., Gao, H., Mu, W., Que, L., Gu, X., Rong, S., Ma, H., Miao, M., Qi, X., Chang, D., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c03012 · Cited by 19
Erlotinib in the first-line treatment of non-small-cell lung cancer
D’Arcangelo, M., & Cappuzzo, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.23 · Cited by 19
In Silico Identification of Significant Detrimental Missense Mutations of EGFR and Their Effect with 4-Anilinoquinazoline-Based Drugs
Rajasekaran, R., & Sethumadhavan, R. (2009) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-009-8662-4 · Cited by 19
Modeling the effect of pathogenic mutations on the conformational landscape of protein kinases
Saladino, G., & Gervasio, F. L. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.01.005 · Cited by 23
Structural Basis for the Inhibition of Cyclin G‐Associated Kinase by Gefitinib
Ohbayashi, N., Murayama, K., Kato-Murayama, M., Kukimoto‐Niino, M., Uejima, T., Matsuda, T., Ohsawa, N., Yokoyama, S., Nojima, H., & Shirouzu, M. (2018) · ChemistryOpen · doi:10.1002/open.201800177 · Cited by 19
Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase
Tavakoli, F., & Ganjalikhany, M. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217031 · Cited by 19
“Moreover, L858R-mutant EGFR (EGFRL858R) enhances the catalytic activity as much as 20–50 fold than WT-EGFR [10, 21].”
Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches
Sato, T., Sekimata, K., Sakai, N., Watanabe, H., Mishima-Tsumagari, C., Taguri, T., Matsumoto, T., Fujii, Y., Handa, N., Tanaka, A., et al. (2020) · ACS Omega · doi:10.1021/acsomega.9b04245 · Cited by 19
Identification of luteolin -7-glucoside and epicatechin gallate fromVernoniacinerea, as novel EGFR L858R kinase inhibitors against lung cancer: Docking and simulation-based study
Maiti, P., Nand, M., Joshi, T., Ramakrishnan, M. A., & Chandra, S. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1784791 · Cited by 20
Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers
Sato, H., Offin, M. D., Kubota, D., Yu, H. A., Wilhelm, C., Toyooka, S., Somwar, R., Kris, M. G., & Ladanyi, M. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.019 · Cited by 18
Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma
Wang, T., Zhang, Q., Wang, N., Liu, Z., Zhang, B., & Zhao, Y. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666201013162144 · Cited by 19
Dynamic Protein Allosteric Regulation and Disease
Nussinov, R., Tsai, C.-J., & Jang, H. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-8719-7_2 · Cited by 18
EGFR inhibitors across generations: Progress, challenges, and future directions
Deshmukh, V. G., Sapkal, S. B., Gadekar, S. S., & Deshmukh, V. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142326 · Cited by 20
Tumor Antigen-Specific Monoclonal Antibodies and Induction of T-Cell Immunity
Trivedi, S., Jie, H.-B., & Ferris, R. L. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.003 · Cited by 18
“The cell surface targets for these antibodies in higher concentration in malignant cells compared to healthy cells.(13) Binding of these mAbs to their cognate receptors results in blockade of downstream signal transduction and subsequent inhibition of proliferative, survival and antiapoptotic pathways.”
Rational Design of Threo as Well Erythro Noscapines, an Anticancer Drug: A Molecular Docking and Molecular Dynamic Approach
Vishvakarma, V. K., Singh, P., Kumari, K., & Chandra, R. (2017) · Biochemistry & Pharmacology Open Access · doi:10.4172/2167-0501.1000229 · Cited by 18
Molecular dynamics, MM/PBSA and in vitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening
Ornnork, N., Kiriwan, D., Lirdprapamongkol, K., Choowongkomon, K., Svasti, J., & Eurtivong, C. (2020) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2020.107639 · Cited by 18
Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Fluorinated Candidates as PI3K Inhibitors: Targeting Fluorophilic Binding Sites
Tantawy, A. H., El‐Behairy, M. F., Abd‐Allah, W. H., Jiang, H. X., Wang, M., & Marzouk, A. A. E. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01674 · Cited by 18
Pharmacophore modeling, virtual screening, molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: An in-silico approach
Matada, G. S. P., Dhiwar, P. S., Abbas, N., Singh, E., Ghara, A., Patil, R. B., & Raghavendra, N. M. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132531 · Cited by 18
Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients
van de Stadt, E. A., Yaqub, M. M., Schuit, R. C., Bartelink, I. H., Leeuwerik, A. F., Schwarte, L. A., Langen, A. J. D., Hendrikse, H., & Bahce, I. (2022) · Diagnostics · doi:10.3390/diagnostics12040883 · Cited by 18
Synthesis of Quinoline‐Thiazolidine‐2,4‐dione Coupled Pyrazoles as in vitro EGFR Targeting Anti‐Breast Cancer Agents and Their in silico Studies
Bangaru, M., Nukala, S. K., Kannekanti, P. K., Narsimha, S., Manchal, R., & Thirukovela, N. S. (2023) · ChemistrySelect · doi:10.1002/slct.202204414 · Cited by 18
Targeting EGFR mutants with non-cognate kinase inhibitors in non-small cell lung cancer
Wang, B., Shen, W., Yang, H., Shen, J., & Sun, T. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1012-2 · Cited by 18
“…(Clark et al., 2005), such as the G719S and L858R that confer constitutive activation for the kinase by disrupting its auto inhibitory interactions (Yun et al., 2007), and the ‘‘gatekeeper’’ mutation T790M that has been reported to primarily associate with acquired drug resistance by increasing…”
Background
Quantum coupled mutation finder: predicting functionally or structurally important sites in proteins using quantum Jensen-Shannon divergence and CUDA programming
Gültaş, M., Düzgün, G., Herzog, S., Jäger, S., Meckbach, C., Wingender, E., & Waack, S. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-96 · Cited by 18
“10 of the QCMF-significant residue sites are in contact with either catalytic residues or critical active site regions for gefitinib binding site in wild type EGFR kinase [34,37,48] (see Figure 1 and Figure 2).”
Background
In silico screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound database
Sawatdichaikul, O., Hannongbua, S., Sangma, C., Wolschann, P., & Choowongkomon, K. (2011) · Journal of Molecular Modeling · doi:10.1007/s00894-011-1135-z · Cited by 18
“The docking approaches were validated with three known inhibitors from crystal structure complexes; erlotinib, gefitinib and AEE788 (PDB code: 1M17, 2ITO and 2J6M) [26, 30 ].”
BackgroundMethod
Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment
Saxon, J. A., Sherrill, T. P., Polosukhin, V. V., Sai, J., Zaynagetdinov, R., McLoed, A. G., Gulleman, P. M., Barham, W. J., Cheng, D., Hunt, R. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1168549 · Cited by 18
Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor
Bommu, U. D., Konidala, K. K., Pamanji, R., & Yeguvapalli, S. (2018) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2018.1426603 · Cited by 18
“The L858R or G719S and G719S/T790M double mutations in the EGFR kinase domain were recently reported [10,11].”
Background
How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFRL858R/T790M/C797S Inhibitors: A Molecular Dynamics Simulation Study
Jingwen, E., Liu, Y., Guan, S., Luo, Z., Han, F., Han, W., Wang, S., & Zhang, H. (2020) · Molecules · doi:10.3390/molecules25040895 · Cited by 19
Peptide-tiling screens of cancer drivers reveal oncogenic protein domains and associated peptide inhibitors
Ford, K. M., Panwala, R., Chen, D.-H., Portell, A. J., Palmer, N. D., & Mali, P. (2021) · Cell Systems · doi:10.1016/j.cels.2021.05.002 · Cited by 22
“The P-loop of EGFR is involved in ATP binding, while the conformationally sensitive autoinhibitory C-helix plays a regulatory role in controlling EGFR enzymatic activity (Yun et al., 2007; Ruan and Kannan, 2018).”
Background
Combating Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Lovly, C. M. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e165 · Cited by 19
“The T790M mutation is thought to confer TKI resistance through steric hindrance which interferes with drug binding and/or through alterations in the ATP affinity of the EGFR kinase (24).”
Background
Rationalizing the binding and α subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies
Golani, L. K., Mian, M. Y., Ahmed, T., Pandey, K. P., Mondal, P., Sharmin, D., Rezvanian, S., Witkin, J. M., & Cook, J. M. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128637 · Cited by 18
Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing
Feng, H., Wang, X., Zhang, Z., Tang, C., Ye, H., Jones, L. E., Lou, F., Zhang, D., Jiang, S., Sun, H., et al. (2015) · Cancer Informatics · doi:10.4137/cin.s22941 · Cited by 19
Self-citation
Molecular and Genetic Pathogenesis of Lung Cancer: Differences Between Small-Cell and Non-Small-Cell Carcinomas
Kitamura, H., Yazawa, T., Okudela, K., Shimoyamada, H., & Sato, H. (2008) · The Open Pathology Journal · doi:10.2174/1874375700802010106 · Cited by 18
“Thus, the genes related to EGFR signaling pathway are candidates for targeted therapies, as exemplified by the treatment of lung ADC having EGFR mutations with tyrosine kinase inhibitors [40, 41].”
Background
Proximity extracellular protein-protein interaction analysis of EGFR using AirID-conjugated fragment of antigen binding
Yamada, K., Shioya, R., Nishino, K., Furihata, H., Hijikata, A., Kaneko, M. K., Kato, Y., Shirai, T., Kosako, H., & Sawasaki, T. (2023) · Nature Communications · doi:10.1038/s41467-023-43931-7 · Cited by 18
“Ge ﬁ ti-nib binds to the ATP binding site of EGFR and suppresses its phos-phorylations in the presence of EGF 45,46 .”
Background
EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025) · Advanced Science · doi:10.1002/advs.202505785 · Cited by 19
Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis
OuYang, P., Su, Z. Z., Mao, Y., Deng, W., & Xie, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079000 · Cited by 18
“Based on the kinetics of the wild type and mutant kinases in vitro, the L858R mutant was 50-fold more active than the wild-type kinase [26].”
Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant
Qin, M., Wang, T., Xu, B., Ma, Z., Jiang, N., Xie, H., Gong, P., & Zhao, Y. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.09.031 · Cited by 17

Authors: Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J.
Affiliations: Harvard University (US)
Dana-Farber Cancer Institute (US)
Broad Institute (US)
Corresponding author: Eck, Michael J.
ORCID: Yun, Cai-Hong
Boggon, Titus J.
Li, Yiqun
Greulich, Heidi
Meyerson, Matthew
Eck, Michael J.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2007-03
Volume: 11
Issue: 3
Pages: 217-227
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2006.12.017
PMC: PMC1939942
OpenAlex: W2111109297
Cited by: 1,192
References: 54
Citations by year: 2026: 58 · 2025: 75 · 2024: 78 · 2023: 84 · 2022: 79 · 2021: 59 · 2020: 72 · 2019: 49 · 2018: 58 · 2017: 57 · 2016: 55 · 2015: 79 · 2014: 63 · 2013: 74 · 2012: 51
FWCI: 40.77
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2366 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (CA116020, CA080942)
Leukemia and Lymphoma Society
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords: EGFR, non-small cell lung cancer, EGFR mutation, L858R, kinase activation, gefitinib, AEE788, staurosporine, kinase inhibitor binding, crystal structure, catalytic acceleration, inhibitor sensitivity
MeSH terms: Gefitinib, Lapatinib, Antineoplastic Agents, Binding Sites, Carcinoma, Non-Small-Cell Lung, Enzyme Activation, Humans, Lung Neoplasms, Models, Molecular, Mutation, Protein Conformation, Purines, Quinazolines, Protein Structure, Tertiary, Crystallography, X-Ray, Staurosporine, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks